Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: Recent surveillance has identified the emergence of the SARS-CoV-2 Omicron variant, which carries up to 36 mutations in the spike protein and has the potential to evade vaccine-induced immunity. This study found that individuals vaccinated with mRNA vaccines exhibited strong neutralization of the Omicron variant, while most vaccinees had weak neutralization. The study also revealed that the Omicron variant infects more efficiently than other tested variants.
Article
Infectious Diseases
David Shasha et al.
Summary: In this study, individuals vaccinated with the Pfizer BNT162b2 vaccine were compared with unvaccinated controls, showing no association between vaccination and Bell's palsy, herpes zoster, or GBS. However, vaccinated individuals were more likely to experience symptoms of numbness or tingling. The study provides reassuring data regarding the safety of the BNT162b2 vaccine.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Article
Medicine, Research & Experimental
Matthew Zirui Tay et al.
Summary: The study found that the Delta variant of the SARS-CoV-2 virus can infect vaccinated individuals. Vaccine breakthrough cases showed lower memory B cell frequencies against the SARS-CoV-2 receptor-binding domain, but antibodies secreted by memory B cells retained neutralizing properties against the Delta variant. Inflammatory cytokines were lower in vaccine breakthrough infections compared to primary infections, highlighting the importance of vaccination in preventing inflammation.
EMBO MOLECULAR MEDICINE
(2022)
Article
Medicine, General & Internal
Aditi Halder et al.
Summary: This study reports on the safety of the Pfizer/BioNtech BNT162b2 vaccine in an Australian vaccination clinic and shows low rates of adverse reactions post-vaccination. Results also suggest possible predisposing factors for rare allergic reactions to the vaccine.
INTERNAL MEDICINE JOURNAL
(2022)
Article
Immunology
Siew-Wai Fong et al.
Summary: This study reveals that patients infected with the Delta 382 SARS-CoV-2 variant have an enhanced adaptive immune response, characterized by an enrichment of genes related to T cell functionality, a more robust SARS-CoV-2-specific T cell immunity, and a quicker antibody response.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Article
Immunology
Victoria G. Hall et al.
Summary: Delayed dosing intervals can enhance immune response to COVID-19 vaccination, including virus neutralization against wild-type and variant viruses. This finding has significant implications for the global implementation of vaccines.
Article
Biochemistry & Molecular Biology
Henning Gruell et al.
Summary: This study demonstrates that neutralization of the SARS-CoV-2 Omicron variant is greatly reduced in individuals who received two doses of the COVID-19 vaccine or have recovered from the disease, but is significantly increased after a booster vaccine dose.
Article
Medicine, General & Internal
Lisa M. Dunkle et al.
Summary: The NVX-CoV2373 vaccine has shown to be safe and highly effective in preventing Covid-19, with a vaccine efficacy of 90.4% against reverse-transcriptase-polymerase-chain-reaction-confirmed cases and 100% efficacy against moderate-to-severe disease. The vaccine also demonstrated high efficacy against various variants of the virus.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Nick Andrews et al.
Summary: A study conducted in England showed that vaccines against SARS-CoV-2 provide high protection against hospitalization and death from Covid-19 at 20 weeks or more after vaccination. However, the effectiveness of the vaccines decreases over time, especially in individuals aged 65 and older and those with underlying risk factors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Rolando Pajon et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Helen Parry et al.
Summary: Delaying the second dose of the BNT162b2 vaccine can significantly boost antibody response in older people, providing a longer period of protection and delaying the need for booster vaccination. However, in terms of cellular-specific response, the best results were achieved with the standard vaccine interval.
Article
Infectious Diseases
Eric J. Haas et al.
Summary: The nationwide vaccination campaign in Israel has successfully prevented a large number of SARS-CoV-2 infections, hospitalizations, and deaths, especially among individuals aged 65 years and older. The full vaccination of the population has played a significant role in controlling the pandemic.
LANCET INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Laurent Renia et al.
Summary: Understanding the impact of age on vaccinations is crucial for designing and delivering vaccines against SARS-CoV-2. This study analyzed the immune responses in 312 individuals vaccinated with the BNT162b2 mRNA vaccine and found that two doses induced high antibody and T cell responses in most individuals. However, antibody recognition of Delta and Omicron variants was less efficient compared to the ancestral Wuhan strain. Age-stratified analysis revealed a group of low antibody responders, predominantly in individuals aged 60 and above. Waning of antibody and cellular responses was observed in 30% of vaccine recipients after 6 months, but age did not influence this decline. Individuals aged 60 and above took longer to develop vaccine-induced immunity but had more sustained acquired immunity at 6 months post-vaccination. A third dose significantly boosted antibody responses against the ancestral Wuhan strain, Delta, and Omicron variants in older individuals.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Rebecca P. Payne et al.
Summary: The study demonstrates that the first dose of the BNT162b2 mRNA vaccine can induce protection against the B.1.1.7 variant within weeks, and extending the interval between doses can result in higher levels of neutralizing antibody response. Prior infection with the virus can accelerate the immune response.
Article
Medicine, General & Internal
Alasdair P S Munro et al.
Article
Immunology
Bei Wang et al.
Summary: The rapid spread of SARS-CoV-2 variants B.1.1.7 from the UK and B.1.351 from South Africa has led to a second wave of COVID-19 cases globally. Antibody-mediated neutralization activity was reduced for B.1.1.7 and significantly attenuated for B.1.351, cautioning against solely relying on RBD mutations to evaluate vaccine efficacy. The study highlights the need for new SARS-CoV-2 vaccines not solely based on the ancestral Spike gene sequence.
Article
Medicine, General & Internal
Nicola P. Klein et al.
Summary: This study conducted interim analysis of safety surveillance data of mRNA COVID-19 vaccines and found that the incidence of selected serious outcomes within 1-21 days post-vaccination was not significantly higher compared with 22-42 days post-vaccination. Surveillance is ongoing despite wide confidence intervals for many outcomes.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Alejandro Jara et al.
Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemical Research Methods
Yun Shan Goh et al.
Summary: Early detection of infected individuals is crucial in managing COVID-19, and a flow cytometry-based assay has been developed to efficiently detect antibodies against SARS-CoV-2 in patients.
Article
Cell Biology
Yun Shan Goh et al.
Summary: Early detection of infection is crucial in limiting the spread of COVID-19, and a flow cytometry-based assay has been developed to detect SARS-CoV-2 spike protein antibodies in COVID-19 patients. The antibody response is significantly higher in later stages of infection, and the assay can also detect antibodies in asymptomatic individuals with high sensitivity, demonstrating its potential for serological analysis of both symptomatic and asymptomatic infections.
CELL REPORTS MEDICINE
(2021)
Article
Multidisciplinary Sciences
Chek Meng Poh et al.
NATURE COMMUNICATIONS
(2020)
Article
Medicine, General & Internal
Kizzmekia S. Corbett et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Multidisciplinary Sciences
Ugur Sahin et al.
Article
Medicine, General & Internal
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Virology
KM Lip et al.
JOURNAL OF VIROLOGY
(2006)
